Obesity is associated with lower plasma levels of natriuretic peptides, which may contribute to hypertension and related disorders. The study analyzed data from 3389 Framingham Study participants to examine the relationship between body mass index (BMI) and plasma levels of B-type natriuretic peptide (BNP) and N-terminal proatrial natriuretic peptide (N-ANP). Multivariable regression analyses showed that lean individuals had higher BNP and N-ANP levels compared to overweight and obese individuals. Obese individuals had higher odds of having low plasma BNP and N-ANP levels compared to lean individuals. Diabetes was also associated with low plasma natriuretic peptide levels, and the negative effects of obesity and diabetes on natriuretic peptide levels were additive. The study found that obesity is independently associated with lower plasma natriuretic peptide levels, independent of hypertension and diabetes. These findings suggest that low plasma natriuretic peptide levels in obese individuals may contribute to their susceptibility to hypertension and related disorders. The study also found that waist circumference was associated with lower plasma natriuretic peptide levels, and that the relationship between BMI and natriuretic peptide levels was consistent across both sexes. The study concluded that obesity is associated with lower plasma natriuretic peptide levels, which may contribute to their susceptibility to hypertension and related disorders. The study also suggested that the natriuretic peptide system may play a role in the pathogenesis of obesity-related hypertension. The study also noted that the findings may have implications for the treatment of hypertension in obese individuals, as the response to exogenous natriuretic peptide therapy may be modified in the setting of obesity. The study also suggested that augmentation of the natriuretic peptide system may reduce the susceptibility of obese individuals to hypertension. The study was limited by its cross-sectional design and the potential for bias due to the detection limits of the assays used.Obesity is associated with lower plasma levels of natriuretic peptides, which may contribute to hypertension and related disorders. The study analyzed data from 3389 Framingham Study participants to examine the relationship between body mass index (BMI) and plasma levels of B-type natriuretic peptide (BNP) and N-terminal proatrial natriuretic peptide (N-ANP). Multivariable regression analyses showed that lean individuals had higher BNP and N-ANP levels compared to overweight and obese individuals. Obese individuals had higher odds of having low plasma BNP and N-ANP levels compared to lean individuals. Diabetes was also associated with low plasma natriuretic peptide levels, and the negative effects of obesity and diabetes on natriuretic peptide levels were additive. The study found that obesity is independently associated with lower plasma natriuretic peptide levels, independent of hypertension and diabetes. These findings suggest that low plasma natriuretic peptide levels in obese individuals may contribute to their susceptibility to hypertension and related disorders. The study also found that waist circumference was associated with lower plasma natriuretic peptide levels, and that the relationship between BMI and natriuretic peptide levels was consistent across both sexes. The study concluded that obesity is associated with lower plasma natriuretic peptide levels, which may contribute to their susceptibility to hypertension and related disorders. The study also suggested that the natriuretic peptide system may play a role in the pathogenesis of obesity-related hypertension. The study also noted that the findings may have implications for the treatment of hypertension in obese individuals, as the response to exogenous natriuretic peptide therapy may be modified in the setting of obesity. The study also suggested that augmentation of the natriuretic peptide system may reduce the susceptibility of obese individuals to hypertension. The study was limited by its cross-sectional design and the potential for bias due to the detection limits of the assays used.